Prostate Cancer Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F
Global prostate cancer therapeutics market is anticipated to grow at an impressive rate through 2028. The multiplication and abnormal enlargement of the prostate gland's aberrant cells in men are known as prostate cancer. Overall, the tenth leading cause of mortality and the sixth major cause of death in men is prostate cancer. Treatments for prostate cancer include surgery, hormone therapy, radiation, chemotherapy, and biological therapy. Prostatic adenocarcinoma, small cell carcinoma, benign prostatic hyperplasia, and other diagnoses and treatments are used to treat and manage prostate cancer.
An aging population, the sedentary lifestyle of those in industrialized nations, and the early start of urological problems are all factors that contribute to the prevalence of prostate cancer, globally. The rise in the geriatric population, upsurge in generic medicines, increasing awareness among people concerning the treatment of prostate cancer, availability of new prostate cancer treatments, and strong emerging pipeline drugs are the factors expected to accelerate the growth of the market. Furthermore, the rise in research and development activities and innovation in drugs is anticipated to boost the growth of the global prostate cancer therapeutics market.
Increasing Elderly Population
Prostate cancer is the most prevalent cancer among men in the US, aside from non-melanoma skin cancer. Additionally, it is one of the major causes of cancer death in males of all races including those of Hispanic ancestry. It is diagnosed in about 6 out of 10 men who are 65 and rare in men under 40. Prostate cancer is the second most common cancer among American males, after lung cancer. In the United States, it was predicted that about 268,490 new cases of prostate cancer were reported in 2022, up from 192,280 new cases in 2009. Moreover, it was estimated that, in 2022, around 34,500 men would die of prostate cancer in the U.S. This, in turn, increased the demand for prostate cancer therapeutics in the US.
Launch of Emerging Novel Therapies
The diagnosis of prostate cancer has transformed owing to advanced diagnostic technologies. The detection of prostate cancer has been assisted by the monitoring of PSA levels. Phase II and phase III trials are underway for several novel cytotoxic medications, hormonal treatments, and other anti-prostate-specific membrane antigen therapies. The Mayo Foundation for Medical Education and Research (MFMER) states that a targeted immune response can be induced against prostate tumors using a combination of hormonal and anti-cytotoxic T-lymphocyte-associated antigen (CTLA) treatment approaches. Hence, innovation in therapies is expected to enhance the growth of the global Prostate Cancer Therapeutics Market. Further, product launches and innovation in medicines by key market players have anticipated booming the growth of the global Prostate Cancer Therapeutics Market.
Side Effects of Hormonal Treatment
Prostate Cancer is a chronic disease with lengthy treatments. The side effects of hormonal treatment include erectile dysfunction, hot flashes, loss of bone density, bone fractures, loss of muscle mass and physical strength, changes in blood lipids, insulin resistance, weight gain, mood swings, fatigue, and the growth of breast tissue (gynecomastia). Hence, long exposure to hormonal treatment affects individuals’ daily life and increases the risk of health problems.
Moreover, side effects vary from person to person and the dose used to treat cancer. Hence, the side effects of cancer treatment are projected to hamper the growth of the market.
Market Segmentation
The global Prostate Cancer Therapeutics Market is segmented based on treatment and end user. Based on treatment, the market is categorized into hormonal therapy, chemotherapy, immunotherapy, and target therapy. Hormonal therapy is further divided into Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists, Hormone-Releasing Hormone (LHRH) Agonists, and Anti-Androgen. The chemotherapy therapy segment is bifurcated into Taxotere and Jevtana. The immunotherapy segment includes Provenge and targeted therapy includes Xofigo and Others. The end-user segment is further segmented into Hospitals, Specialized Clinics, Ambulatory Surgical Centers, and Others.
Recent Developments
- The introduction of CAMCEVI (leuprolide), a 42mg injection emulsion for the treatment of adults with advanced prostate cancer was announced by BioPharma in March 2022. The business also provides access to the AccordConnects mobile application for the administration of Camcevi inventories.
Johnson & Johnson; Services Inc.; Astellas Pharma Inc.; Eli Lilly and Company; Sanofi; Ipsen Pharma; Bayer AG; AstraZeneca; Valeant Pharmaceuticals International, Inc.; Merck & Co., Inc.; Pfizer Inc are the major players operating in the global prostate cancer therapeutics market.
Report Scope:
In this report, the global Prostate Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Prostate Cancer Therapeutics Market, By Treatment:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- Anti-Androgen
- Chemotherapy
- Taxotere
- Jevtana
- Immunotherapy
- Provenge
- Targeted Therapy
- Xofigo
- Others
- Prostate Cancer Therapeutics Market, By End User:
- Hospitals
- Specialized Clinics
- Ambulatory Surgical centers
- Others
- Prostate Cancer Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- UAE
- South Arabia
- Saudi Africa
- Turkey
- Egypt
Company Profiles: Detailed analysis of the major companies present in the Global Prostate Cancer Therapeutics Market.
Available Customizations:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
- 1. Service Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
- 2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
- 3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
- 4. Voice of Customer
- 5. Global Prostate Cancer Therapeutics Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
- 5.2.1.1. Hormonal Therapy
- 5.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
- 5.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- 5.2.1.1.3. Anti-Androgen
- 5.2.1.2. Chemotherapy
- 5.2.1.2.1. Taxotere
- 5.2.1.2.2. Jevtana
- 5.2.1.3. Immunotherapy
- 5.2.1.3.1. Provenge
- 5.2.1.4. Target Therapy
- 5.2.1.4.1. Xofigo
- 5.2.1.5. Others
- 5.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2022)
- 5.3. Market Map
- 5.3.1. By Treatment
- 5.3.2. By End User
- 6. North America Prostate Cancer Therapeutics Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
- 6.2.1.1. Hormonal Therapy
- 6.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
- 6.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- 6.2.1.1.3. Anti-Androgen
- 6.2.1.2. Chemotherapy
- 6.2.1.2.1. Taxotere
- 6.2.1.2.2. Jevtana
- 6.2.1.3. Immunotherapy
- 6.2.1.3.1. Provenge
- 6.2.1.4. Target Therapy
- 6.2.1.4.1. Xofigo
- 6.2.1.5. Others
- 6.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
- 6.2.3. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Prostate Cancer Therapeutics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Treatment
- 6.3.1.2.2. By End User
- 6.3.2. Canada Prostate Cancer Therapeutics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Treatment
- 6.3.2.2.2. By End User
- 6.3.3. Mexico Prostate Cancer Therapeutics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Treatment
- 6.3.3.2.2. By End User
- 7. Europe Prostate Cancer Therapeutics Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
- 7.2.1.1. Hormonal Therapy
- 7.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
- 7.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- 7.2.1.1.3. Anti-Androgen
- 7.2.1.2. Chemotherapy
- 7.2.1.2.1. Taxotere
- 7.2.1.2.2. Jevtana
- 7.2.1.3. Immunotherapy
- 7.2.1.3.1. Provenge
- 7.2.1.4. Target Therapy
- 7.2.1.4.1. Xofigo
- 7.2.1.5. Others
- 7.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Prostate Cancer Therapeutics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Treatment
- 7.3.1.2.2. By End User
- 7.3.2. Germany Prostate Cancer Therapeutics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Treatment
- 7.3.2.2.2. By End User
- 7.3.3. United Kingdom Prostate Cancer Therapeutics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Treatment
- 7.3.3.2.2. By End User
- 7.3.4. Italy Prostate Cancer Therapeutics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Treatment
- 7.3.4.2.2. By End User
- 7.3.5. Spain Prostate Cancer Therapeutics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Treatment
- 7.3.5.2.2. By End User
- 8. Asia-Pacific Prostate Cancer Therapeutics Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
- 8.2.1.1. Hormonal Therapy
- 8.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
- 8.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- 8.2.1.1.3. Anti-Androgen
- 8.2.1.2. Chemotherapy
- 8.2.1.2.1. Taxotere
- 8.2.1.2.2. Jevtana
- 8.2.1.3. Immunotherapy
- 8.2.1.3.1. Provenge
- 8.2.1.4. Target Therapy
- 8.2.1.4.1. Xofigo
- 8.2.1.5. Others
- 8.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
- 8.2.3. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Prostate Cancer Therapeutics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Treatment
- 8.3.1.2.2. By End User
- 8.3.2. Japan Prostate Cancer Therapeutics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Treatment
- 8.3.2.2.2. By End User
- 8.3.3. India Prostate Cancer Therapeutics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Treatment
- 8.3.3.2.2. By End User
- 8.3.4. South Korea Prostate Cancer Therapeutics Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Treatment
- 8.3.4.2.2. By End User
- 8.3.5. Australia Prostate Cancer Therapeutics Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Treatment
- 8.3.5.2.2. By End User
- 9. South America Prostate Cancer Therapeutics Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
- 9.2.1.1. Hormonal Therapy
- 9.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
- 9.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- 9.2.1.1.3. Anti-Androgen
- 9.2.1.2. Chemotherapy
- 9.2.1.2.1. Taxotere
- 9.2.1.2.2. Jevtana
- 9.2.1.3. Immunotherapy
- 9.2.1.3.1. Provenge
- 9.2.1.4. Target Therapy
- 9.2.1.4.1. Xofigo
- 9.2.1.5. Others
- 9.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Prostate Cancer Therapeutics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Treatment
- 9.3.1.2.2. By End User
- 9.3.2. Argentina Prostate Cancer Therapeutics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Treatment
- 9.3.2.2.2. By End User
- 9.3.3. Colombia Prostate Cancer Therapeutics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Treatment
- 9.3.3.2.2. By End User
- 10. Middle East and Africa Prostate Cancer Therapeutics Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
- 10.2.1.1. Hormonal Therapy
- 10.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
- 10.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- 10.2.1.1.3. Anti-Androgen
- 10.2.1.2. Chemotherapy
- 10.2.1.2.1. Taxotere
- 10.2.1.2.2. Jevtana
- 10.2.1.3. Immunotherapy
- 10.2.1.3.1. Provenge
- 10.2.1.4. Target Therapy
- 10.2.1.4.1. Xofigo
- 10.2.1.5. Others
- 10.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. UAE Prostate Cancer Therapeutics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Treatment
- 10.3.1.2.2. By End User
- 10.3.2. Saudi Arabia Prostate Cancer Therapeutics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Treatment
- 10.3.2.2.2. By End User
- 10.3.3. Saudi Africa Prostate Cancer Therapeutics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Treatment
- 10.3.3.2.2. By End User
- 10.3.4. Turkey Prostate Cancer Therapeutics Market Outlook
- 10.3.4.1. Market Size & Forecast
- 10.3.4.1.1. By Value
- 10.3.4.2. Market Share & Forecast
- 10.3.4.2.1. By Treatment
- 10.3.4.2.2. By End User
- 10.3.5. Egypt Prostate Cancer Therapeutics Market Outlook
- 10.3.5.1. Market Size & Forecast
- 10.3.5.1.1. By Value
- 10.3.5.2. Market Share & Forecast
- 10.3.5.2.1. By Treatment
- 10.3.5.2.2. By End User
- 11. Market Dynamics
- 11.1. Drivers
- 11.1.1. Increasing Prevalence of Prostate Cancer.
- 11.1.2. Adoption of Novel Screening and Diagnostic Technologies
- 11.1.3. Surge in Research and Development
- 11.2. Challenges
- 11.2.1. High Cost of Cancer Treatment
- 11.2.2. Side Effects of Hormonal Treatment
- 12. Market Trends & Developments
- 12.1. Product Launches
- 12.2. Mergers & Acquisitions
- 12.3. Technological Advancements
- 13. Clinical Trial Analysis
- 14. Global Prostate Cancer Therapeutics Market: SWOT Analysis
- 15. Competitive Landscape
- 15.1. Business Overview
- 15.2. Product Offerings
- 15.3. Recent Developments
- 15.4. Financials (In Case of Listed Companies)
- 15.5. Key Personnel
- 15.6. SWOT Analysis
- 15.6.1. Johnson & Johnson Services, Inc.
- 15.6.2. Astellas Pharma Inc.
- 15.6.3. Eli Lilly and Company
- 15.6.4. Sanofi S.A.
- 15.6.5. Ipsen Pharma
- 15.6.6. Bayer AG
- 15.6.7. AstraZeneca Plc
- 15.6.8. Valeant Pharmaceuticals International, Inc.
- 15.6.9. Merck & Co., Inc.
- 15.6.10. Pfizer Inc.
- 16. Strategic Recommendations
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook